Last update :
18/04/2024
InfoStab
Infostab
List of drugs
List of drugs
Summary lists
Summary lists
Search for compatibilities
Search for compatibilities
Y-site compatibility table
Y-site compatibility table
References
References
Research teams
Research teams
Valistab
Valistab
Poster
Poster
Links
Links
Sponsors
Sponsors
Authors
Authors
User’s guide
User’s guide
Newsletter
Newsletter
Anticancer drug   Cisplatin  
Injection
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References Pdf
   Chemical structure  

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers
Abiplatin Republic of South Africa
Accocit Mexico
Briplatin Japan
Cisplatex Brazil
Cisplatin Australia, Austria, Belgium, Canada, Saudi Arabia
Cisplatina Brazil
Cisplatine Belgium, France
Cisplatyl France, Greece, Saudi Arabia, Turkey
Citoplatino Argentina, Italy
Citoplax Brazil
Corsis Mexico
Insel Brazil
Neoplatin Spain
Pamifect India
Placis Spain, Turkey
Platamine Greece, Italy, Morocco, Tunisia
Platanovag Argentina
Platiblastin Austria
Platidiam Hungary, Poland
Platinex Germany, Great Britain, Italy
Platinol Austria, Belgium, Denmark, Finland, Greece, Luxembourg, Mexico, Netherlands, Sweden, Switzerland, United States of America
Platistil Spain
Platistine Belgium, Brazil, Luxembourg
Platosin Belgium, Egypt, Greece, Japan, Netherlands, Romania, Turkey, Venezuela
Pronto Platamine Italy
Zuridry Mexico
Stability of mixtures   Injection   Stability of mixtures : Cisplatin     
Container Solvent Concentration Compound Temperature Storage Duration of stability References
Glass Sodium chloride 0,9% 0,2 mg/ml
Injection   Cisplatin   
Injection   Etoposide 0,2 & 0,4 mg/ml
20,5°C-24°C
48 Hour
Protect from light 417
Level of evidence D
Glass Sodium chloride 0,9% 0,5 mg/ml
Injection   Cisplatin   
Injection   Granisetron hydrochloride 0,5 mg/ml
20°C-23°C
4 Hour
Protect from light 57
Level of evidence A+
Glass Sodium chloride 0,9% 0,25 mg/ml
Injection   Cisplatin   
Injection   Palonosetron hydrochloride 25 µg/ml
?
4 Hour
Not specified 1950
Level of evidence A+
Polyvinyl chloride Sodium chloride 0,9% 0,455 mg/ml
Injection   Cisplatin   
Injection   Ondansetron hydrochloride 1,091 mg/ml
2-8°C
24 Hour
Protect from light 53
Level of evidence C
Polyvinyl chloride Sodium chloride 0,9% 0,2 mg/ml
Injection   Cisplatin   
Injection   Etoposide 0,2 & 0,4 mg/ml
20,5°C-24°C
48 Hour
Protect from light 417
Level of evidence D
Polyvinyl chloride Sodium chloride 0,9% 0,1 mg/ml
Injection   Cisplatin   
Injection   Potassium chloride 2,9 mEq/l
Injection   Magnesium sulfate 1,9 mg/ml
25°C
28 Day
Protect from light 3183
Level of evidence A+
Polyvinyl chloride Sodium chloride 0,9% 0,455 mg/ml
Injection   Cisplatin   
Injection   Ondansetron hydrochloride 1,091 mg/ml
30°C
168 Hour
Protect from light 53
Level of evidence C
Polyvinyl chloride Glucose 5% 0,05 & 0,2 mg/ml
Injection   Cisplatin   
Injection   Magnesium sulfate 1 & 2 mg/ml
Injection   Mannitol 18,75 mg/ml
-15°C
30 Day
Protect from light 1080
Manufacturer's stability data
Polyvinyl chloride Glucose 5% 0,05 & 0,2 mg/ml
Injection   Cisplatin   
Injection   Magnesium sulfate 1 & 2 mg/ml
Injection   Mannitol 18,75 mg/ml
25°C
48 Hour
Not specified 1080
Manufacturer's stability data
Polyvinyl chloride Glucose 5% 0,05 & 0,2 mg/ml
Injection   Cisplatin   
Injection   Mannitol 18,75 mg/ml
Injection   Magnesium sulfate 1 & 2 mg/ml
4°C
4 Day
Protect from light 1080
Manufacturer's stability data
Not specified NaCl 0,9% or Glucose 5% 0,084 mg/ml
Injection   Cisplatin   
Injection   Topotecan 0,028 mg/ml
20°C-23°C
4 Hour
Light 1026
Level of evidence C
  Mentions Légales